6:19 PM
 | 
Feb 02, 2009
 |  BC Extra  |  Top Story

Tarceva-Avastin combo meets endpoint

Genentech (NYSE:DNA) said a DSMB recommended ending the Phase IIIb ATLAS trial for first-line treatment of non-small cell lung cancer (NSCLC) after an interim analysis showed that Tarceva erlotinib plus Avastin bevacizumab met the primary endpoint of significantly improving...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >